Trial Profile
Open-label salvage study of cancer vaccine in patients with advanced, inoperable hepatocellular carcinoma with elevated serum levels of alpha-fetoprotein (AFP) biomarker
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2015
Price :
$35
*
At a glance
- Drugs Hepcortespenlisimut-L (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Pharmacodynamics
- 07 Sep 2015 New trial record